SCHEMBL3561799

SCHEMBL3561799

CCOC(=O)C(CC(=O)O)c1nc(-n2ccnc2)ns1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
ATM Q13315 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NOS2 P35228 6/20 0.39
NOS1 P29475 2/20 0.39
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
MITF O75030 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CTSA P10619 1/20 0.35
CD38 P28907 3/20 0.34
CDC7 O00311 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
CYP26A1 O43174 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566117 0.75 NOS2 (0.57) NOS2NOS1ALDH1A1
SCHEMBL3562683 0.73 MEN1 (0.44) KDM4ETSHRMAPK1ATMTDP1
Hydrazine SCHEMBL3567840 0.70 TSHR (0.37) TSHRMAPK1TDP1NOS2NOS1
Hydrazine SCHEMBL3559520 0.69 TSHR (0.38) TSHRMAPK1TDP1NOS2NOS1
SCHEMBL13037127 0.66 LMNA (0.42) TSHRMAPK1TDP1NOS2NOS1
SCHEMBL3557965 0.66 CYP3A4 (0.46) TSHRMAPK1TDP1NOS2MEN1
SCHEMBL19877340 0.65 ALDH1A1 (0.48) KDM4ETDP1ALDH1A1MAPTKMT2A
SCHEMBL3560003 0.64 TSHR (0.43) KDM4ETSHRMAPK1ATMTDP1
SCHEMBL25485897 0.63 KDM4E (0.45) KDM4ETSHRMAPK1ATMTDP1
SCHEMBL3559041 0.62 NOS2 (0.44) KDM4ETSHRMAPK1ATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 KDM4E 1567/4885TSHR 788/4885MAPK1 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.